Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMD-477 in Type 1 Diabetes
NCT02715193Phase 1Completed
- Sponsor
- REMD Biotherapeutics, Inc.
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing REMD-477 with Placebo (2 arms). Primary endpoints: Number of treatment emergent adverse events per subject at 57 days and Changes from baseline in 24-hour insulin requirements at Day 4. Started Mar 2016; status: completed.
02
Drugs
volagidemab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02715193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715193.